The University of Rostock (Universität Rostock), founded in 1419, stands as Germany's second-oldest university and a prominent center for neurodegenerative disease research in Northern Germany. Located in the historic Baltic Sea port city of Rostock in the state of Mecklenburg-Vorpommern, the university has built a comprehensive research program targeting the molecular mechanisms underlying Alzheimer's disease, Parkinson's disease, prion diseases, and amyotrophic lateral sclerosis (ALS). Through its strategic partnership with the German Center for Neurodegenerative Diseases (DZNE) and its state-of-the-art research facilities, the University of Rostock contributes significantly to both basic science discoveries and translational research aimed at developing disease-modifying therapies.
The institution's research portfolio spans from fundamental studies of protein misfolding and aggregation to clinical biomarker validation and therapeutic intervention trials. The Center for Translational Neurodegeneration serves as the hub for interdisciplinary research bringing together molecular biologists, biochemists, clinicians, and computational scientists in a collaborative environment designed to accelerate the translation of basic findings into clinical applications.
The University of Rostock traces its origins to 1419, making it one of the oldest universities in continuous operation in the world. The medical faculty, established in the university's early years, has evolved significantly over the past six centuries, adapting to changing scientific paradigms and emerging research challenges. The modern era of neurodegeneration research at Rostock began in the late 1990s with the establishment of dedicated prion disease research programs, led by pioneering work on cerebrospinal fluid biomarkers including the 14-3-3 protein [@otto1999].
The early 2000s saw expansion of research focus beyond prion diseases to encompass the full spectrum of neurodegenerative conditions. The establishment of the Center for Translational Neurodegeneration in 2010 marked a pivotal moment in the institutional research strategy, consolidating diverse research groups under a unified framework dedicated to understanding disease mechanisms and developing therapeutic interventions. This consolidation enabled the formation of interdisciplinary research teams combining expertise in molecular biology, protein biochemistry, neuroimaging, and clinical neurology.
The university's membership in the German Center for Neurodegenerative Diseases (DZNE) network, beginning in 2012, further elevated its research profile and provided access to multi-center clinical studies and collaborative research programs spanning the entire spectrum of neurodegenerative diseases. This partnership has been particularly valuable for conducting the large-scale biomarker studies and clinical trials that are essential for translating basic science discoveries into clinical practice.
The University of Rostock maintains a comprehensive set of research facilities specifically designed to support cutting-edge neurodegeneration research. The infrastructure includes specialized laboratories for handling prion agents under Biosafety Level 3 (BSL-3) conditions, reflecting the institution's historical strength in prion disease research. The Prion Laboratory, certified for work with transmissible spongiform encephalopathies, enables researchers to investigate the molecular mechanisms of prion propagation and test potential therapeutic compounds in appropriate containment settings.
The Transgenic Animal Facility houses mouse models of various neurodegenerative diseases, including transgenic lines expressing mutant proteins associated with Alzheimer's disease (APPswe/PSEN1), Parkinson's disease (α-synuclein A53T), and ALS (SOD1, TDP-43). These models enable researchers to study disease progression in vivo and test therapeutic interventions before clinical translation. The facility maintains both conventional and specific pathogen-free (SPF) housing areas, with dedicated space for behavioral testing and longitudinal observation of disease phenotypes.
The Protein Characterization Suite provides access to advanced instrumentation for biophysical analysis of aggregating proteins, including dynamic light scattering (DLS), circular dichroism (CD) spectroscopy, fluorescence correlation spectroscopy (FCS), and atomic force microscopy (AFM). These technologies enable researchers to characterize the aggregation kinetics and structural properties of disease-associated proteins, providing insights into the molecular mechanisms of toxicity and identifying potential therapeutic targets.
The Clinical Research Unit coordinates patient recruitment and clinical data collection for neurodegeneration studies, maintaining standardized protocols for cognitive assessment, neuroimaging, and biomarker sampling. This infrastructure supports both investigator-initiated studies and multi-center clinical trials conducted through the DZNE network.
The University of Rostock maintains one of Europe's leading programs in prion disease research, building on decades of experience in studying Creutzfeldt-Jakob disease (CJD) and related conditions. The prion research program encompasses several interconnected research areas, including biomarker development, disease mechanism elucidation, and therapeutic target identification.
The pioneering work on cerebrospinal fluid 14-3-3 protein as a diagnostic marker for sporadic CJD, initiated in the late 1990s, established international standards for prion disease diagnosis and remains a cornerstone of clinical diagnostic protocols [@otto1999]. Subsequent research has refined this biomarker approach and identified additional CSF markers that enhance diagnostic accuracy, including tau protein and neurofilament light chain measurements [@zerr2022].
Current prion research programs focus on understanding the structural basis of prion protein (PrP) conversion and the mechanisms by which pathological prions propagate within the nervous system. Studies employ a combination of biochemical, biophysical, and cell biological approaches to investigate how the normal cellular prion protein (PrP^C) transforms into the disease-associated isoform (PrP^Sc). This work has identified specific structural intermediates in the conversion process that represent potential therapeutic targets [@zimmermann2024].
The development of therapeutic approaches for prion diseases represents a major research priority. Researchers at Rostock have contributed to the identification of several compounds that inhibit prion replication in cell culture and animal models, including compounds targeting PrP expression, stability, and aggregation. The translation of these findings to clinical application requires careful evaluation of drug delivery, blood-brain barrier penetration, and safety profiles, ongoing areas of investigation through pre-clinical and early clinical studies.
Research on Alzheimer's disease (AD) at the University of Rostock encompasses the full spectrum from basic mechanism studies to clinical biomarker validation and therapeutic trials. The research program addresses multiple aspects of AD pathogenesis, including amyloid-β aggregation, tau pathology, neuroinflammation, and synaptic dysfunction.
Studies on amyloid-β metabolism investigate the enzymatic pathways involved in amyloid precursor protein (APP) processing, focusing on the beta- and gamma-secretases that generate the amyloid-β peptide. Understanding the regulation of these enzymes and their role in amyloid plaque formation informs the development of pharmacological inhibitors aimed at reducing amyloid-β production. Additional research examines the mechanisms by which amyloid-β aggregates exert neurotoxic effects, including disruption of synaptic function, perturbation of calcium homeostasis, and induction of oxidative stress.
The tau research program investigates the post-translational modifications that accompany tau pathology, including phosphorylation, acetylation, and truncation. These modifications are thought to promote tau aggregation into neurofibrillary tangles and enhance tau toxicity. Researchers employ cellular and animal models to determine which modifications are causally involved in disease progression and identify the kinases and phosphatases that regulate them.
Neuroinflammation has emerged as a critical component of AD pathogenesis, and the Rostock research program includes substantial work on the role of microglia and astrocytes in disease progression. Studies investigate how neuroinflammation contributes to neuronal loss and whether modulating immune responses might provide therapeutic benefits [@stangel2020]. The relationship between genetic risk factors (particularly APOE) and neuroinflammatory responses represents an active area of investigation.
Clinical research at Rostock contributes to multi-center studies coordinated through the DZNE network, including studies on early detection biomarkers, lifestyle interventions, and pharmacological treatments. The clinical cohort studies follow patients from prodromal stages through mild cognitive impairment to established dementia, enabling characterization of disease progression and identification of predictors of rapid decline [@hermann2021].
The Parkinson's disease research program at the University of Rostock focuses on understanding the mechanisms underlying alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation—the cardinal pathological features of the disease. Research combines analysis of human postmortem tissue, patient-derived biomarkers, and animal models to elucidate disease mechanisms and identify therapeutic targets.
Alpha-synuclein research addresses the factors that trigger the transition of the normally soluble protein into pathological aggregates. Studies examine post-translational modifications that promote aggregation (including phosphorylation at Ser129 and truncation), the role of cellular quality control systems (autophagy and the ubiquitin-proteasome system) in preventing aggregate formation, and the mechanisms by which aggregates spread between neurons [@siegert2019].
Mitochondrial dysfunction represents a central theme in Parkinson's disease research, given the well-established involvement of mitochondrial complex I deficiency in disease pathogenesis. Studies investigate the mechanisms underlying mitochondrial impairment, including the effects of environmental toxins (such as MPTP and rotenone), genetic factors affecting mitochondrial function, and the role of mitochondrial quality control pathways. The relationship between mitochondrial dysfunction and alpha-synuclein pathology is a particular focus, as evidence suggests these processes may be mutually reinforcing [@friedrich2023].
Clinical research on Parkinson's disease encompasses movement disorder clinics that provide specialized care for patients and serve as recruitment sites for clinical trials. Studies address non-motor symptoms (including cognitive impairment, autonomic dysfunction, and sleep disorders) that significantly impact patient quality of life. Research also focuses on identifying biomarkers that predict disease progression and monitor treatment response.
The ALS research program at the University of Rostock investigates the pathogenic mechanisms underlying motor neuron degeneration, with particular focus on the role of TDP-43 proteinopathy, which characterizes the majority of ALS cases. Research addresses both familial forms of ALS (including mutations in SOD1, FUS, and C9orf72) and sporadic disease, which represents approximately 90% of cases.
Studies on TDP-43 pathology investigate the mechanisms by which TDP-43 aggregation leads to neuronal dysfunction and death. Research examines the effects of TDP-43 loss of normal function (including disrupted RNA metabolism and altered splicing) and the toxic effects of aggregates. The relationship between ALS and frontotemporal dementia (FTD), which shares common pathological features, is investigated through studies of overlapping genetic risk factors and shared molecular mechanisms [@huber2023].
The identification of neurofilament light chain (NfL) as a biomarker for ALS progression represents a significant contribution from the field [@steinacker2022]. Measurement of NfL in cerebrospinal fluid and blood provides a marker of axonal damage that correlates with disease progression and can be used to monitor treatment response in clinical trials. This work has contributed to the standardization of biomarker approaches across ALS research centers.
Research on therapeutic interventions includes both pharmacological approaches targeting known disease mechanisms and rehabilitation strategies aimed at maintaining function. The translation of basic science findings into clinical trials requires careful selection of appropriate outcome measures and patient populations, an area where the Rostock team contributes expertise gained through participation in multi-center studies.
The University of Rostock serves as one of ten sites of the German Center for Neurodegenerative Diseases (DZNE), a nationally funded research center that brings together expertise from across Germany to accelerate progress in understanding and treating neurodegenerative diseases. This partnership provides substantial benefits for the university's research program, including access to shared resources, participation in multi-center clinical studies, and collaborative projects with other leading institutions.
The DZNE research strategy emphasizes translational research that bridges the gap between basic science discoveries and clinical application. This approach aligns well with the strengths of the Rostock research program, which has historically combined fundamental mechanism studies with clinical investigation. Through DZNE, researchers at Rostock contribute to large-scale studies that would be impossible to conduct at a single institution, including biomarker discovery projects, genetic association studies, and clinical trials.
Specific DZNE initiatives that involve the University of Rostock include the Dementia Research Initiatives, which aim to identify early biomarkers of disease and develop interventions that can be implemented before significant neurodegeneration occurs. The ALS research network coordinated through DZNE enables standardized data collection and sample sharing across German centers, facilitating the large-scale studies needed to identify disease modifiers and therapeutic targets.
The training mission of DZNE includes support for early-career researchers, providing opportunities for doctoral students and postdoctoral fellows to train in interdisciplinary research environments. The Rostock site contributes to this mission by hosting fellows and facilitating exchange between basic and clinical research programs.
The University of Rostock serves as a hub for neuroscience collaboration in the Baltic Sea region, leveraging its geographic position to establish connections with research institutions in Northern Europe and the Baltic states. This regional network facilitates exchange of expertise, sharing of resources, and collaborative research projects that address questions of regional relevance.
The Baltic Sea Neuroscience Initiative brings together researchers from universities in Sweden, Denmark, Poland, Lithuania, Latvia, Estonia, and Finland to address common questions in neurodegeneration research. Areas of collaboration include biomarker standardization, clinical trial methodology, and the development of registries for neurodegenerative diseases. The shared interest in protein aggregation diseases reflects the strong prion research tradition in the region, with contributions from multiple centers [@engelhardt2021].
Regional collaboration also extends to student and researcher exchange programs, enabling trainees to gain experience at different institutions and benefit from diverse scientific perspectives. These programs support the development of a new generation of neuroscientists equipped to address the complex challenges of neurodegenerative disease research.
The University of Rundeck offers comprehensive training programs in neurodegeneration research through multiple pathways. The doctoral program in Molecular Medicine includes specialized tracks in neuroscience and neurodegeneration, providing students with rigorous training in molecular biology, biochemistry, and cellular neuroscience. The curriculum combines coursework in relevant disciplines with extensive research experience in laboratory settings.
The Medical Doctor/PhD program provides opportunities for physicians to gain research training while maintaining clinical competency. This pathway is particularly valuable for individuals pursuing academic careers that combine patient care with research, a model that is especially important for translational research in neurodegeneration.
Postdoctoral training positions offer advanced research experience in specialized laboratories, preparing fellows for independent research careers. The diversity of research programs at Rostock enables postdoctoral fellows to gain expertise in multiple complementary approaches, including molecular biology, protein biochemistry, animal modeling, and clinical research.
Clinical training in neurology includes specialized instruction in neurodegenerative diseases, with exposure to the full spectrum of conditions encountered in movement disorder and memory disorder clinics. The integration of clinical training with research opportunities enables the development of physician-scientists who can contribute to both patient care and scientific advance.
The University of Rostock has articulated several strategic priorities for the coming years that build on existing strengths while addressing emerging opportunities in neurodegeneration research. The expansion of biomarker research represents a major focus, with the goal of identifying blood-based markers that can be used for early detection and disease monitoring. These biomarkers would complement existing CSF markers and enable broader population screening.
Therapeutic development remains a central priority, with specific programs targeting prion diseases, Alzheimer's disease, and ALS. The translation of basic science findings into clinical application requires careful attention to target validation, drug development, and clinical trial design. The partnership with DZNE provides essential infrastructure for conducting the rigorous clinical studies needed to demonstrate efficacy.
The integration of computational approaches into neurodegeneration research represents an emerging priority. Machine learning algorithms can analyze complex datasets to identify patterns predictive of disease onset or progression, complementing traditional hypothesis-driven research. The establishment of computational biology capabilities within the Center for Translational Neurodegeneration will support this strategic direction.
International collaboration will continue to expand, building on existing partnerships while establishing new connections with leading institutions worldwide. The goal is to participate in the global research effort to understand neurodegenerative diseases while contributing unique expertise from the Rostock research program.
The University of Rostock's research connects with numerous other topics in NeuroWiki: